Trial Profile
A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer) Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With Intravenous Iron Sucrose in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Ferric derisomaltose (Primary) ; Iron sucrose
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Pharmacosmos
- 13 Jun 2014 New trial record